



NEW MOLECULAR TECHNOLOGIES LTD.

FOUNDED

in **2012**

CORE OF THE INNOVATION

The technology allows discovering defects (oncomutations) simultaneously in the set of all the most important genes that are connected with oncological disease development in humans.

IMPLEMENTATION OF THE DEVELOPMENT

SHOULD BE IMPLEMENTED IN **2014**,
AND BE INTRODUCED INTO CLINICAL
PRACTICE ALREADY IN **2016**

APPLICATIONS

In clinical practice it can be used for early diagnostics, treatment optimization and monitoring of all kinds of malignant tumors.

PEOPLE

GENERAL DIRECTOR:
Maxim A. Pavlenko, PhD in Immunobiology
and in Cancer Immunology

This technology allows analyzing DNA received both from the tumor tissue and biological liquids (blood, urine, saliva).

Peculiarities of the technology:

- 1** It surpasses global analogues in sensitivity and reliability in discovering oncomutations;
- 2** There will be only one test needed for testing the whole set of the most important regulatory human genes;
- 3** There will be a possibility to detect all possible oncomutations in the genes under analysis;
- 4** It will allow fast growth of the researched genes list when new regulatory genes will be discovered in the future.
 - In the nearest future profiling of the cancer tumor – reliable analysis of all oncomutations in the most important regulatory genes – will enter the everyday clinical practice.
 - The technology under development should allow creating the testing systems with the sensitivity of 1 mutant DNA copy per 100,000 copies of the wild type that will be suitable for profiling of all kinds of malignant tumors.
 - At the moment there are no ready products or services with similar qualities in the world market. According to expert estimations, such technologies will enter the clinical practice in 3-5 years.

